

FOI 2888

20th February 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Response:

6 newly diagnosed DLBCL patients (July – Dec 24)

Of these patients, how many commenced treatment at your trust within the last 6 months?

Response:

5 commenced treatment with Southern Health and Social Care Trust.

In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)

R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)

(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)

R-GemOX (rituximab, gemcitabine and oxaliplatin)

Axicabtagene ciloleucel

Tisagenlecleucel

Epcoritamab

Loncastuximab tesirine

Glofitamab

Any other SACT

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Response:

This information is not recorded centrally. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel

Pola-BR (polatuzumab vedotin with rituximab and bendamustine)

R-GemOX (rituximab, gemcitabine and oxaliplatin)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatments

Response:

This information is not recorded centrally. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.



Southern Health and Social Care Trust

In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Response:

This information is not recorded centrally. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel)

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Any other treatment

Response:

<5

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net